Juno Therapeutics (NASDAQ: JUNO) and Endocyte (NASDAQ:ECYT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Juno Therapeutics and Endocyte’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Juno Therapeutics -354.36% -27.10% -20.97%
Endocyte -61,437.14% -32.68% -31.29%

Earnings & Valuation

This table compares Juno Therapeutics and Endocyte’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Juno Therapeutics $82.57 million 57.05 -$288.55 million ($2.82) -15.93
Endocyte $70,000.00 2,736.96 -$40.60 million ($1.02) -4.41

Endocyte has higher revenue, but lower earnings than Juno Therapeutics. Juno Therapeutics is trading at a lower price-to-earnings ratio than Endocyte, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.2% of Juno Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Endocyte shares are held by institutional investors. 15.3% of Juno Therapeutics shares are held by company insiders. Comparatively, 14.9% of Endocyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Juno Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the S&P 500. Comparatively, Endocyte has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Juno Therapeutics and Endocyte, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Juno Therapeutics 1 6 8 0 2.47
Endocyte 0 1 2 0 2.67

Juno Therapeutics currently has a consensus target price of $42.12, indicating a potential downside of 6.20%. Endocyte has a consensus target price of $7.00, indicating a potential upside of 55.56%. Given Endocyte’s stronger consensus rating and higher possible upside, analysts clearly believe Endocyte is more favorable than Juno Therapeutics.

Summary

Juno Therapeutics beats Endocyte on 8 of the 13 factors compared between the two stocks.

About Juno Therapeutics

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

About Endocyte

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.